You are here

Share:

Product Type

Development Stage

Therapeutic Area

Institutes and Centers

Search Technologies

Showing 41-60 of 134 results found

RNA/DNA Nanoparticles as Cancer Therapeutics

The technology is directed to the use of single-stranded RNA overhangs or toeholds of varying lengths (< 12 nucleotides) contained in nucleic acid-based nanoparticles which trigger the association of these nanoparticles and activates multiple functionalities such as gene silencing and/or cell-specific targeting. The use of RNA toeholds is superior to that of DNA toeholds in that it allows for smaller nanoparticles (fewer nucleotides for the toeholds) resulting in greater chemical stability, less immunogenic and higher yield of production. The National Cancer Institute (NCI) seeks licensing and/or co-development research collaborations for use of RNA overhangs or toeholds in nucleic acid nanoparticles.
  • Therapeutics

Nanoparticle-hydrogel Composite for Nucleic Acid Molecule Delivery

The National Cancer Institute (NCI) seeks research a co-development partner and/or licensees for applications utilizing the nanoparticle platform technology for delivery of cancer-specific microRNAs, particularly for therapeutic uses in surface cancers, such as mesothelioma.
  • Therapeutics

Fusion Proteins as HIV-1 Entry Inhibitors

Novel fusion proteins with good stability and potency against HIV-1. These fusion proteins have good drug properties and potential as prophylactics or therapeutics against HIV-1 infection. Researchers at the NCI seek licensing for the development and commercialization of novel fusion proteins as therapeutics or prophylactics against HIV-1 infection.
  • Therapeutics

Antibody and Immunotoxin Treatments for Mesothelin-expressing Cancers

The National Cancer Institute Laboratory of Molecular Biology is seeking statements of capability or interest from parties interested in licensing or collaborative research to further develop, evaluate, or commercialize antibody-based treatments of mesothelin-expressing cancers.
  • Therapeutics

Small Molecule Inhibitors of Drug Resistant Forms of HIV-1 Integrase

Researchers at the National Cancer Institute discovered small-molecule compounds whose activity against HIV-1 integrase mutants confer greater resistance than currently approved INSTIs. Preliminary DMPK and ADME studies have been completed by the NCI researchers. The National Cancer Institute seeks partners to commercialize this class of compounds through licensing or co-development.
  • Therapeutics

Potassium Hydroxy Citrate Promotes Longevity and Efficacy of Anti-Tumor T cells for Adoptive Cell Therapy (ACT)

Adoptive cell therapy (ACT) using tumor-specific T cells leads to complete tumor regression in some cancer patients. However, limiting the efficacy of this therapy is that T cells become functionally exhausted and have short half-lives after adoptive transfer. Researchers at the National Cancer Institute (NCI) have discovered a novel method to generate long-lived memory tumor-specific T cells with enhanced tumor clearance and persistence upon in vivo transfer. NCI is seeking parties interested in licensing and/or co-developing potassium hydroxy citrate to promote longevity and efficacy of tumor-specific T cells.
  • Therapeutics

PIM-Targeted PROTACs

The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a series of PIM Kinase targeting PROTACS.
  • Therapeutics

Polymeric Delivery Platform for Therapeutics

The National Cancer Institute (NCI) seeks licensing and/or co-development research collaborations for a polymeric drug delivery platform that targets scavenger receptor A1 (SR-A1), a receptor highly expressed in macrophages, monocytes, mast cells, dendritic cells (myeloid lineages), and endothelial cells. The platform delivers various immunomodulatory therapeutic cargo including small molecule drugs, therapeutic peptides, and vaccines, to the lymphatic system and myeloid/antigen presenting cell (APC) sub-populations.
  • Therapeutics

T cell Receptors Which Recognize Mutated EGFR

Researchers at the National Cancer Institute (NCI) have isolated T cell receptors (TCRs) that target specific mutations in the epidermal growth factor receptor (EGFR). The mutated protein recognized by these TCRs is frequently expressed in non-small cell lung cancer (NSCLC). These TCRs can be used for a variety of therapeutic applications, including engineered adoptive cell immunotherapy. Researchers at the NCI seek licensing and/or co-development research collaborations for these novel T cell receptors that recognize EGFR mutations.
  • Therapeutics

CD206 Small Molecule Modulators, Their Use and Methods for Preparation

Researchers at the National Cancer Institute (NCI) have discovered a small molecule that binds to CD206 and activates M2-like tumor associated macrophages resulting in innate and adaptive anti-tumor responses. NCI seeks research co-development or licensees for CD206 small molecule modulators as a therapeutic for CD206-expressing cancers (such as pancreatic, sarcoma, head and neck, lung, gastric, triple negative breast, renal cell, colorectal cancer, melanoma).
  • Therapeutics

Monoclonal Antibodies and Immunoconjugates Directed to the Non-ShedPortion (“Stalk”) of Mesothelin are Excellent Candidates for Developing Therapeutic Agents

Antibodies that specifically recognize and bind to the unshed portion (“stalk”) of human mesothelin are strong therapeutic candidates because they maintain contact with the cancer cell for a longer duration than other anti-mesothelin antibodies that are currently available. The National Cancer Institute (NCI) has developed such antibodies that specifically recognize and bind to the stalk of human mesothelin with high affinity. The NCI seeks licensing and/or co-development research collaborations to advance the development and commercialization of these antibodies.
  • Therapeutics

Overexpression of Phf19 on T Cells Enhances Therapeutic Effects of T Cell-Based Therapies (such as Chimeric Antigen Receptor [CAR] Therapies)

Researchers at the National Cancer Institute (NCI) have developed a method to epigenetically reprogram CD8+ T cell fate by expressing elevated levels of the polycomb-like protein, Phf19. This technology is useful for improving T cell-based immunotherapies (such as CAR therapies) to treat a range of infectious diseases and cancers. NCI seeks licensing or co-development partners for this invention.
  • Therapeutics

IgG4 Hinge Containing Chimeric Antigen Receptors Targeting Glypican-1 For Treating Solid Tumors

Researchers at the National Cancer Institute have developed a glypican-1 (GPC1) chimeric antigen receptor (CAR)-T cells using short immunoglobin subclass 4 (IgG4) hinge sequences that are highly potent against GPC1-expressing tumors. NCI seeks research co-development partners and/or licensees to advance the development of GPC1-IgG4 hinge CARs for the treatment of pancreatic cancer and other GPC1-expressing tumors.
  • Therapeutics

Combination of Near Infrared Photoimmunotherapy Targeting Cancer Cells and Host-Immune Activation

Investigators at the National Cancer Institute (NCI) seek co-development partners and/or licensees for a new therapeutic approach that selectively targets cancer cells and prevents tumor regrowth. The novel method combines antibody-IR700 molecules and Near-Infrared Photo Immunotherapy (NIR-PIT), which has shown great potential in targeting tumors via a host immunogenic response, with already known and available anti-cancer immunomodulators to further enhance the antitumor response. The investigators have shown in mouse models that, when used in combination, NIR-PIT-treatment and standard antitumor agents conferred a potent vaccine-like effect, not only curing mice of local and distant cancers but successfully immunizing them against tumor regrowth.
  • Therapeutics

Pages